SCHEMBL444177

SCHEMBL444177

CCc1ccc(N2N=C(C)C(=Cc3ccc(O)cc3)C2=O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AMY1A P0DUB6 5/20 0.56
KAT8 Q9H7Z6 2/20 0.56
KMT2A Q03164 8/20 0.55
MEN1 O00255 6/20 0.55
L3MBTL1 Q9Y468 4/20 0.55
PTGS2 P35354 1/20 0.51
ALDH1A1 P00352 3/20 0.48
HPGD P15428 2/20 0.48
GAA P10253 2/20 0.48
KDM4E B2RXH2 2/20 0.48
MAPT P10636 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
THRB P10828 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
HSD17B10 Q99714 1/20 0.48
POLB P06746 2/20 0.47
SIRT5 Q9NXA8 1/20 0.47
USP2 O75604 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL420572 1.00 AMY1A (0.56) AMY1AKAT8KMT2AMEN1L3MBTL1
SCHEMBL420802 0.85 KAT8 (0.60) AMY1AKAT8KMT2AMEN1L3MBTL1
SCHEMBL446710 0.85 KAT8 (0.60) AMY1AKAT8KMT2AMEN1L3MBTL1
SCHEMBL446711 0.85 KAT8 (0.60) AMY1AKAT8KMT2AMEN1L3MBTL1
SCHEMBL420808 0.84 KMT2A (0.76) AMY1AKAT8KMT2AMEN1L3MBTL1
SCHEMBL446478 0.84 KMT2A (0.76) AMY1AKAT8KMT2AMEN1L3MBTL1
SCHEMBL8078405 0.82 KAT8 (0.81) AMY1AKAT8KMT2AMEN1L3MBTL1
SCHEMBL443203 0.82 KAT8 (0.81) AMY1AKAT8KMT2AMEN1L3MBTL1
SCHEMBL14562410 0.82 KAT8 (0.66) AMY1AKAT8KMT2AMEN1L3MBTL1
SCHEMBL420591 0.82 KAT8 (0.81) AMY1AKAT8KMT2AMEN1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140335517-A1 DETECTION AND TREATMENT OF SCHIZOPHRENIA RENASCIENCE CO LTD (JP) 2014-11-13 US disclosed
US-8809329-B2 Detection and treatment of schizophrenia TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE (JP) 2014-08-19 US disclosed
EP-2662453-A2 Detection and treatment of schizophrenia TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2013-11-13 EP disclosed
US-20120065198-A2 Detection and Treatment of Schizophrenia TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2012-03-15 US disclosed
US-20110028470-A1 Detection and Treatment of Schizophrenia TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2011-02-03 US disclosed
EP-2189537-A1 DETECTION AND TREATMENT OF SCHIZOPHRENIA TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2010-05-26 EP disclosed
US-7645882-B2 Inhibitor of protein modification products formation TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2010-01-12 US disclosed
US-20070123577-A1 Inhibitor of protein modification products formation TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2007-05-31 US disclosed
EP-1693369-A1 PROTEIN MODIFIER PRODUCTION INHIBITOR TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) 2006-08-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123577-A1 Inhibitor of protein modification products formation SERPINB6, PROC, PLPBP AMY1A 1685/4885KAT8 2951/4885KMT2A 2334/4885
US-20110028470-A1 Detection and Treatment of Schizophrenia GLO1, CBR1, AOX1 AMY1A 1713/4885KAT8 2833/4885KMT2A 1703/4885
US-20120065198-A2 Detection and Treatment of Schizophrenia GLO1, CBR1, AOX1 AMY1A 1713/4885KAT8 2833/4885KMT2A 1703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.